Franklin Biotechnology Discovery Fund A Acc USD

富蘭克林生物科技新領域基金 A類 Acc 美元

LU0109394709

Risk Rating: Level 5

iFund risk rating methodology is a qualitative and quantitative assessment of a single fund’s geographic and asset class focus, investment style and any potential risk factors, as measured from one (1) (lowest risk) to six (6) (highest risk). For the funds with risk rating five (5) or six (6), these are mainly aimed at providing capital appreciation to investors by investing primarily in single market equities, single industry equities or derivatives etc. For more details, please refer to the Due Diligence section under the Procedures page.

On Holiday

Dealing Information

Secure Transaction

Derivatives knowledge not required

HKD10,000.00Min. Subscription

1.00%

HKD10,000.00Min. Subscription

USD

HKD10,000.00Min. Subscription

HKD10,000.00

HKD10,000.00

Daily

15:30

2019-09-30

*Not include dividends (If applicable)

Fund Performances (including dividend, if any)

1 mth
-1.02%
3 mth
-5.77%
6 mth
-6.30%
1 yr
-8.65%
3 yr
+4.72%
5 yr
+5.52%

Analytical Figures (3 years)

Annualized Return
+1.55%
Annualized Volatility
+22.40%
Sharpe Ratio
+0.15

Fund Information

Fund Houses
Franklin Templeton Investments (Asia) Ltd.
Launch Date
2000-04-02
Fund Manager
Evan S. McCulloch
Steven Kornfeld
Manager Start Date
2000-11-01
2015-09-15
Geographical Focus
Global
Asset Class/ Sector
Equity - Technology related
Risk Rating
Risk Level 5

iFund risk rating methodology is a qualitative and quantitative assessment of a single fund’s geographic and asset class focus, investment style and any potential risk factors, as measured from one (1) (lowest risk) to six (6) (highest risk). For the funds with risk rating five (5) or six (6), these are mainly aimed at providing capital appreciation to investors by investing primarily in single market equities, single industry equities or derivatives etc. For more details, please refer to the Due Diligence section under the Procedures page.

Fund AUM(As of 2019-08-29)
USD 1,692,796,831.201
Management Fee
1.00%
Latest Dividend
N.A.

Sector Leaders

    No Funds

Dealing Information

Secure Transaction

Derivatives knowledge not required

HKD10,000.00Min. Subscription

1.00%

HKD10,000.00Min. Subscription

USD

HKD10,000.00Min. Subscription

HKD10,000.00

HKD10,000.00

Daily

15:30

2019-09-30

Dividend Records

No Dividends

Investment Objective

Franklin Biotechnology Discovery Fund (the "Fund") aims to increase the value of its investments over the medium to long term.
The Fund invests principally (that is, at least two-thirds of the Fund's net assets) in:
- equity securities issued by biotechnology companies located in the U.S. and other countries

Nature and Extent of Risks

Investment involves risks. Please refer to the offering document for details including the risk factors.
1. Market risk
The market values of securities owned by the Fund will tend to go up or down, sometimes rapidly or unpredictably, due to factors affecting individual issuers, particular industries or sectors within securities markets, or because of general market conditions. During a general downturn in the securities markets, multiple asset classes (including different sectors of the same asset class) may decline in value at the same time. Similarly, when markets perform well, there can be no assurance that securities held by the Fund will participate in the advance. Because the securities the Fund holds fluctuate in price in this manner, the Fund's value may go down as well as up and investors may be adversely affected.
2. Equity risk
Equity and equity-linked securities are subject to significant price movements due to various economic, political, market and issuer-specific factors. Such changes may adversely affect the value of equities regardless of issuer-specific performance. Additionally, different industries, financial markets and securities can react differently to these changes. Such fluctuations of the Fund's value are often exacerbated in the short-term. Financial markets trends (including feared or actual failures in the banking system) may also cause large fluctuations in the prices of such securities. As a result, the Fund may be adversely affected.
3. Foreign currency risk
The Fund will typically invest to a significant degree in securities that are denominated in currencies other than the base currency of the Fund, exposing its investments to changes in foreign exchange rates and the possibility of exchange control regulations. Changes in currency exchange rates may adversely affect the value of the Fund, and also may affect the income earned by the Fund and gains and losses realized by the Fund. Furthermore, the total return for a share class that is denominated in a different currency (the "alternative currency") from the base currency of the Fund may be affected, either positively or negatively, by changes in the exchange rate between the Fund's base currency and the alternative currency.
4. Liquidity risk
The Fund may not be able to easily sell securities due to adverse market conditions or reduced value or creditworthiness of issuers in which it invests. The inability of the Fund to sell securities or positions may also impede the ability of the Fund to meet redemption requests in a timely manner. Certain securities may also be illiquid due to limited trading markets or contractual restrictions on their resale. Reduced liquidity due to these factors may have an adverse impact on the net asset value of the Fund.
5. Biotechnology sector risk
The biotechnology sector presents greater risk and higher volatility than investment in a broader range of securities covering many different sectors. The value and performance of the Fund may be adversely affected as a result.
6. Single sector risk
The Fund's investments are concentrated in a single sector. The value of the Fund may be more volatile than that of a fund having a more diverse portfolio of investments and may be more susceptible to adverse economic, political, policy, foreign exchange, liquidity, tax, legal or regulatory events affecting the sector in which it invests.
7. Smaller- and mid-sized companies risk
Stocks of smaller- and mid-sized companies tend to be less liquid and more volatile to adverse economic developments than larger, more recognized companies, particularly if such companies are in emerging markets, which results in higher risk for the Fund. The value and performance of the Fund may be adversely affected as a result.
8. Growth stocks risk
Growth stocks can be more volatile and may be more expensive, relative to earnings, than the market in general. The Fund may be adversely affected by the greater volatility of investments in such stocks.
9. Dividend policy risk
The Fund's dividend policy allows for payment of dividends out of capital or effectively out of capital. Where this is done, it amounts to a return or withdrawal of part of an investor's original investment or from any capital gains attributable to that original investment. Any distributions involving payment of dividends out of the Fund's capital or payment of dividends effectively out of the Fund's capital (as the case may be) may result in an immediate reduction of the net asset value per share.
10. Counterparty risk
The Fund may be exposed to the credit/default risks of its counterparties and the Fund/investors may be adversely impacted.

Manage your asset round-the-clock

Hotline

852
3896 3896

1501, 15/F, 101 King's Road,
North Point, Hong Kong

Mon - Fri (excluding public holidays)
09:00 - 18:00

Copyright © 2019 Noble Apex Advisors Limited. All Rights Reserved.